• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

One Drop Acquires Sano’s Continuous Glucose Sensing Platform

Share:

April 20, 2020

Highlights on this story:
  • One Drop has acquired all the assets and intellectual property of Sano Intelligence, Inc. which include Sano’s continuous glucose sensing platform.
  • One Drop will leverage the acquired assets, including silicon-sensing production infrastructure, to design, produce, and commercialize a painless, silicon-based continuous health sensing platform for use across multiple conditions.

One Drop, a New York City-based provider of digital care solutions for people living with diabetes and other chronic conditions, today announced it has acquired all of the assets and intellectual property of Sano Intelligence, Inc., an innovator in health sensing technology. The deal was structured as an asset purchase, and several Sano team members will be joining One Drop.

Founded in 2011 by Ashwin Pushpala and Raj Gokal, Sano is a biometric sensor that tells you important things about your health by revealing personalized information about how your body metabolizes glucose. The almost decade of work put into developing the Sano continuous glucose sensing platform will live on in a comprehensive multi-sensorial solution from One Drop.

One Drop Integration Plans for Sano

The planned development marks a significant milestone in One Drop’s effort to bring personalized, adaptive, integrated health solutions to people in real time via their mobile phones. One Drop plans to leverage the acquired assets, including silicon-sensing production infrastructure, to design, produce, and commercialize a painless, silicon-based continuous health sensing platform for use across multiple conditions.

“Sano and One Drop have a shared vision of transforming traditional healthcare into proactive, preventative self-care,” said Sano CEO and founder, Ashwin Pushpala. “We are excited to combine our sensor and device expertise with the strength of One Drop’s data-driven predictive capabilities and user-centered design to create a comprehensive collision avoidance system for health and wellness.”

One Drop’s Expanded Diabetes Solution

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

One Drop has expanded its diabetes solution to offer data-driven tools and personalized support for people living with type 1 diabetes, type 2 diabetes, gestational diabetes, prediabetes, high blood pressure, high cholesterol, or any combination of these conditions. At the same time, One Drop has supplemented its direct-to-consumer channels by introducing end-to-end employer and payor offerings, digital-only offerings, and broader retail availability to reach even larger populations. The company’s unique approach combines personal health coaching, connected devices, and AI-powered Predictive Insights to inspire positive behavior change.

To date, One Drop has collected 9 billion longitudinal health data points across 75 biomarkers from nearly 2.5 million users. One Drop’s continuous health sensing platform will add thousands of new data points per user per day, thereby strengthening the machine learning models behind One Drop’s predictive and adaptive support capabilities across multiple conditions.

Financial details of the acquisition were not disclosed.

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Pfizer and Glaxo Close OTC Joint VenturePfizer and Glaxo Close OTC Joint Venture
  • Sparton to Be Acquired by Cerberus for $18.50/ShareSparton to Be Acquired by Cerberus for $18.50/Share
  • Glaukos and Avedro Announce Definitive Acquisition AgreementGlaukos and Avedro Announce Definitive Acquisition Agreement
  • Merck Expands ADC Footprint with $9.3B Kelun Licensing DealMerck Expands ADC Footprint with $9.3B Kelun Licensing Deal
  • BrightInsight Raises $40M in Series B Funding to Cement its Position as the Leading Global Regulated Digital Health Platform for Biopharma and MedtechBrightInsight Raises $40M in Series B Funding to Cement its Position as the Leading Global Regulated Digital Health Platform for Biopharma and Medtech
  • Novartis puts AI on the job to help reps say the right things to the right doctorsNovartis puts AI on the job to help reps say the right things to the right doctors
  • Canopy Growth and Acreage Holdings Announce Filing of Management Information Circulars Related to Canopy’s Plan to Acquire AcreageCanopy Growth and Acreage Holdings Announce Filing of Management Information Circulars Related to Canopy’s Plan to Acquire Acreage
  • Rock Health’s Thoughts on Digital Health Validation, Exit Strategies, Future of Digital TherapeuticsRock Health’s Thoughts on Digital Health Validation, Exit Strategies, Future of Digital Therapeutics

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications